The molecular glue degrader medicines furthest along in development are potential cancer treatments, but Monte Rosa Therapeutics is also researching how this therapeutic modality can treat ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

GLUE, reported positive interim clinical results for several molecular glue degrader programs. The company plans to start multiple Phase 2 studies for MRT-8102 in cardiovascular risk patients and ...

Novartis’s busy summer of dealmaking is continuing, and its latest deal is with a familiar face. The pharmaceutical giant is returning to current partner Monte Rosa Therapeutics to begin a new ...

Bill McColl has 25+ years of experience as a senior producer and writer for TV, radio, and digital media leading teams of anchors, reporters, and editors in creating news broadcasts, covering some of ...

Monte Rosa Therapeutics is capping off a fundraising spree with a $222.3 million IPO to get two of its “molecular glue” treatments into the clinic and advance its other discovery-stage programs. The ...

Interim clinical data from GFORCE-1 trial of NEK7-directed MGD MRT-8102 demonstrated profound CRP reductions in subjects with elevated CVD risk; ...

Monte Rosa Therapeutics is at it again, banking $95 million just six months after reeling in a $96 million series B. The funds will propel the company’s lead protein-degrading program into the clinic ...

Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced the grant of inducement equity ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.